Levron is developing a novel autonomic integrated diagnostic and therapeutic minimally invasive device intended to be used with cardiac failure patients.

The company's device integrates diagnosis and treatment, shifts fluids from the lung, and reduces cardiac workloads.

The device provides adaptive treatment for NYHA stage 3 heart failure, eliminating lung congestion.